<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00698243</url>
  </required_header>
  <id_info>
    <org_study_id>OSI-027-101</org_study_id>
    <secondary_id>2007-006158-25</secondary_id>
    <nct_id>NCT00698243</nct_id>
  </id_info>
  <brief_title>Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma</brief_title>
  <official_title>A Phase 1 Dose-escalation Study of Intermittent, Once Weekly, and Continuous Daily Oral OSI-027 Dosing in Patients With Advanced Solid Tumors or Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the maximum tolerated dose (MTD) and to&#xD;
      establish the recommended phase 2 dose of oral OSI-027 when administered via 3 schedules,&#xD;
      namely, intermittent, weekly, and continuous in patients with advanced solid tumors or&#xD;
      lymphoma, namely, intermittent, weekly, and continuous.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will open with Schedule 1 (S1, intermittent) with initiation of Schedule 2 (S2,&#xD;
      weekly) and Schedule 3 (S3, continuous), which may occur in parallel after observation of&#xD;
      clinically significant related dose limiting toxicity (DLT) in the S1 schedule. Dosing will&#xD;
      be initiated on Day 1 with intermittent weekly dosing continuing for 21 days (1 Treatment&#xD;
      Period). Expansion of Dose Escalation Cohorts may occur for S1 and S2 at the recommended&#xD;
      phase 2 dose level(s) and a Biomarker Expansion Cohort may be opened in S1 and/or S2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile of OSI-027</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of OSI-027</measure>
    <time_frame>up to 23 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary pharmacodynamic relationship with OSI-027 systemic exposure</measure>
    <time_frame>up to 23 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary antitumor activity of OSI-027</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Any Solid Tumor or Lymphoma</condition>
  <arm_group>
    <arm_group_label>Schedule 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily for 3 days every 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Schedule 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Schedule 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OSI-027</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Schedule 1</arm_group_label>
    <arm_group_label>Schedule 2</arm_group_label>
    <arm_group_label>Schedule 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically documented malignancy (solid tumor or lymphoma)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 2&#xD;
&#xD;
          -  Predicted life expectancy of at least 3 months&#xD;
&#xD;
          -  Adequate hematopoietic and hepatic function, and normal renal function&#xD;
&#xD;
          -  Fasting glucose &lt;7mmol/L at baseline&#xD;
&#xD;
          -  Left ventricular ejection fracture (LVEF) by Multiple gated acquisition scan (MUGA)≥&#xD;
             60%&#xD;
&#xD;
          -  Practice effective contraceptive measures throughout study&#xD;
&#xD;
          -  Verbal and written informed consent&#xD;
&#xD;
          -  Prior therapy:&#xD;
&#xD;
               -  Chemotherapy, minimum of 3 weeks and recovered from any treatment-related&#xD;
                  toxicities (except for alopecia, and grade 1 neurotoxicity) prior to registration&#xD;
&#xD;
               -  Hormonal, discontinued prior to registration&#xD;
&#xD;
               -  Radiation, minimum of 21 days and recovered from toxic effects prior to&#xD;
                  registration&#xD;
&#xD;
               -  Surgery, provided wound healing has occurred&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of significant cardiac disease unless well controlled&#xD;
&#xD;
          -  Discontinuation from prior therapy due to cardiac toxicity&#xD;
&#xD;
          -  Active or uncontrolled infections&#xD;
&#xD;
          -  Serious illness or medical condition that could interfere with study participation&#xD;
&#xD;
          -  History of any psychiatric condition that might impair understanding or compliance&#xD;
&#xD;
          -  Documented history of diabetes mellitus&#xD;
&#xD;
          -  Pregnant or breastfeeding females&#xD;
&#xD;
          -  Unstable symptomatic brain metastases, that require steroid or that have required&#xD;
             radiation in the last 28 days&#xD;
&#xD;
          -  Chronic systemic steroid use for cancer related condition&#xD;
&#xD;
          -  History of allergic reactions&#xD;
&#xD;
          -  Patients with cataract who are expected to undergo surgery within 6 months of&#xD;
             registration&#xD;
&#xD;
          -  Use of drugs causing QT interval prolongation within 14 days prior to dosing&#xD;
&#xD;
          -  Patients with clinically significant electrolyte imbalances&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Mardsen Hospital</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>June 13, 2008</study_first_submitted>
  <study_first_submitted_qc>June 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2008</study_first_posted>
  <last_update_submitted>April 11, 2013</last_update_submitted>
  <last_update_submitted_qc>April 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OSI-027</keyword>
  <keyword>Solid tumor</keyword>
  <keyword>Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

